Cerus Revenue and Competitors
Estimated Revenue & Valuation
- Cerus's estimated annual revenue is currently $65.4M per year.
- Cerus received $57.5M in venture funding in February 2018.
- Cerus's estimated revenue per employee is $180,193
- Cerus's total funding is $45M.
Employee Data
- Cerus has 363 Employees.
- Cerus grew their employee count by 1% last year.
Cerus's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Area VP, US Sales, West | Reveal Email/Phone |
2 | VP, Global Marketing | Reveal Email/Phone |
3 | VP National Accounts | Reveal Email/Phone |
4 | VP, Device Development - Disposables & Platelet & Plasma Biology | Reveal Email/Phone |
5 | VP Clinical Development & Operation | Reveal Email/Phone |
6 | VP Hematology and Early Clinical Development | Reveal Email/Phone |
7 | VP, Product Management & Blood Center Services | Reveal Email/Phone |
8 | VP, Microbiology and Platelet & Plasma Biology | Reveal Email/Phone |
9 | VP, Development and Platelets, Plasma and Therapeutics Program Leader | Reveal Email/Phone |
10 | Executive Assistant to CEO and Chief Financial Officer | Reveal Email/Phone |
Cerus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Cerus?
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in late stage clinical development, and the company is also developing an INTERCEPT cryoprecipitate product for the treatment of bleeding complications in trauma, maternal hemorrhage and cardiovascular surgery.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$45M
Total Funding
363
Number of Employees
$65.4M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cerus News
Cerus Corporation (CERS) Stock: Do Analysts Think You Should Accumulate? Monday, April 25, 2022 10:02 AM | InvestorsObserver Analysts. Cerus Corporation...
Under the terms of this contract, Cerus will continue to supply the Red Cross the INTERCEPT Blood System used to produce pathogen reduced...
Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022,...
Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance Accelerating Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $42.1 Million Grew 44% in the Third Quarter Product Revenue of $36.1 Million Grew ...
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third quarter 2021 total revenue of $42.1 million, reflecting a 44% increase over the prior year period. Total revenue was composed of ...
Other Companies in Concord
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $66.7M | 368 | 59% | N/A |
#2 | $86M | 382 | N/A | N/A |
#3 | $139.9M | 386 | 18% | N/A |
#4 | $111.7M | 406 | 9% | N/A |
#5 | $35M | 408 | 8% | N/A |
Cerus Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-09-27 | $6.5M | Department of Defen | Article | |
| 2003-06-09 | $54.3M | Public Offering | Article | |
| 2005-10-06 | $23.0M | Undisclosed | NIAID | Article |
| 2006-12-07 | $26.1M | Undisclosed | Banc of America Securities LLC, Robert W. Baird/Co | Article |
| 2008-06-20 | $10.0M | Undisclosed | Wells Fargo Bank N.A, Expand Commercial Business | Article |
| 2010-04-08 | $10.0M | Undisclosed | Article | |
| 2015-01-08 | $65.5M | Undisclosed | Article | |
| 2018-02-01 | $57.5M | Undisclosed | BTIG, LLC | Article |